|Bid||5.08 x 1400|
|Ask||5.10 x 1300|
|Day's Range||4.99 - 5.20|
|52 Week Range||4.64 - 51.60|
|Beta (3Y Monthly)||2.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.71|
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: ...
Novavax, Inc. (NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™ Phase 3 clinical trial. The U.S. Food & Drug Administration (FDA) has recommended that Novavax conduct an additional Phase 3 clinical trial to confirm efficacy against medically significant RSV disease in infants born to mothers vaccinated with ResVax. Novavax has recently held meetings with several European national regulatory agencies to solicit input on the Prepare trial and possible pathways to licensure in Europe. The next step will be to seek formal scientific advice this fall from the European Medicines Authority (EMA), the agency responsible for licensing vaccines for the European Union.
It’s official: Novavax Inc. will have to complete another clinical trial for its respiratory syncytial virus vaccine candidate for infants, ResVax, lengthening its road to market by roughly three years following its failed phase 3 trial in March. The Gaithersburg biotech has received a letter from the Food and Drug Administration indicating another trial is required before it can earn clearance, said Novavax CEO Stanley Erck in an interview. “We are still heavily focused on RSV,” Erck said, adding: “Yes, it’s going to take a couple years longer and more money than we hoped." The news marks a pivotal moment for Novavax (NASDAQ: NVAX) as it works its way down the regulatory pathways in the U.S. and abroad after ResVax failed to prevent RSV in newborns through maternal immunizations at a high-enough rate in its late-stage trial.
GAITHERSBURG, Md., June 04, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial.
GAITHERSBURG, Md., May 10, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes.
The company will put into effect a reverse stock split of its issued and outstanding common stock, a move intended to increase its share price.
Novavax, Inc. (NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of Incorporation (the Amended Certificate) to effect the reverse stock split at a Special Meeting of Stockholders held on May 8, 2019. The reverse stock split is intended to give Novavax greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Novavax’ common stock to enable Novavax to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Nanoflu vaccine updatesOn January 3, Novavax (NVAX) issued a press release announcing positive top-line results from a Phase 2 trial that compared multiple
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Resvax vaccine updatesOn February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM, evaluating the
Is Novavax an Attractive Pick after First-Quarter Results?Stock price movementsNovavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Gaithersburg, Maryland-based company said it had a loss of 11 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
GAITHERSBURG, Md., May 01, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and.
GAITHERSBURG, Md., April 25, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of.